PDCD1 and melanoma: In three ongoing expansion cohorts of patients with advanced melanoma, preliminary results from anti-PD-1/PD-L1-naïve patients reported an ORR of 61.2%, and patients who had disease progression after prior anti-PD-1 adjuvant treatment had an ORR of 61.5% (28).